18 Sep 2025 | 5 Mins Read
Biocon shares jump 2% on USFDA approval for new osteoporosis treatments
Flipitmoney
Biocon shares surged 2% to Rs 361.25 after its subsidiary Biocon Biologics received FDA approval for two denosumab biosimilars, Bosaya and Aukelso, with provisional interchangeability designation for broader market adoption. The approved biosimilars treat osteoporosis and multiple myeloma, with market potential despite Biocon's year-to-date 4% losses.